Literature DB >> 26311564

Role of inflammation in benign prostatic hyperplasia development among Han Chinese: A population-based and single-institutional analysis.

Jimeng Hu1, Limin Zhang1, Lujia Zou1, Mengbo Hu1, Jie Fan2, Yehua Cai3, Gang Xu1, Jie Fang1, Qiang Ding1, Haowen Jiang1.   

Abstract

OBJECTIVES: To explore whether asymptomatic inflammatory prostatitis is associated with prostatic enlargement beyond that of benign prostatic hyperplasia patients without asymptomatic inflammatory prostatitis, and whether asymptomatic inflammatory prostatitis affects long-term outcomes of transurethral resection of the prostate.
METHODS: The present study involved 106 benign prostatic hyperplasia patients who underwent transurethral resection of the prostate. Clinical and pathological parameters were compared between those with benign prostatic hyperplasia associated with asymptomatic inflammatory prostatitis and those with benign prostatic hyperplasia alone.
RESULTS: A total of 55 patients (52%) were found to have benign prostatic hyperplasia and asymptomatic inflammatory prostatitis, whereas 51 patients (48%) had benign prostatic hyperplasia alone. The prostate volume of the benign prostatic hyperplasia/asymptomatic inflammatory prostatitis group was significantly larger than the benign prostatic hyperplasia alone group: 68.1 cm3 (interquartile range 45.7-86.3) versus 44.1 cm3 (interquartile range 30.9-72.1), P = 0.036. In terms of histopathological analysis, benign prostatic hyperplasia/asymptomatic inflammatory prostatitis patients were more likely to show mild (53%), focal (67%) and stromal (40%) prostatic inflammation in our study. Furthermore, statistically significant differences of International Prostate Symptom Score were found 3 years after transurethral resection of the prostate, with benign prostatic hyperplasia/asymptomatic inflammatory prostatitis patients reporting higher (worse) scores than benign prostatic hyperplasia alone patients (P = 0.025).
CONCLUSIONS: Chronic prostatic inflammatory process might progressively conduce to benign prostatic hyperplasia development, which can also result in prostate enlargement and worsen long-term postoperative International Prostate Symptom Scores. Multicenter studies with larger cohorts and longer follow-up periods are required to confirm these findings.
© 2015 The Japanese Urological Association.

Entities:  

Keywords:  asymptomatic inflammatory prostatitis; benign prostatic hyperplasia; histopathological classification; outcomes; transurethral resection of the prostate

Mesh:

Year:  2015        PMID: 26311564     DOI: 10.1111/iju.12914

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  6 in total

1.  Clinical optimal dose of solifenacin succinate for nursing patients after transurethral resection of the prostate during the perioperative period.

Authors:  Baodi Zhang; Jia Wei; Xuan Wu; Lei Wang; Hongdan Huo; Junrong Wang
Journal:  Exp Ther Med       Date:  2017-11-27       Impact factor: 2.447

2.  Clinical Importance of Histopathological Inflammation in Patients with Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Prospective Study of 222 Patients.

Authors:  Thibault Meert; Evert Baten; Koenraad van Renterghem
Journal:  Curr Urol       Date:  2017-07-30

Review 3.  Management of BPH then 2000 and now 2016 - From BPH to BPO.

Authors:  Johan Braeckman; Louis Denis
Journal:  Asian J Urol       Date:  2017-03-30

4.  The effect of prostatic inflammation on clinical outcomes in patients with benign prostate hyperplasia.

Authors:  Suleyman Sami Cakir; Emre Can Polat; Levent Ozcan; Huseyin Besiroglu; Alper Ötunctemur; Emin Ozbek
Journal:  Prostate Int       Date:  2018-01-08

5.  Kangquan Recipe Regulates the Expression of BAMBI Protein via the TGF-β/Smad Signaling Pathway to Inhibit Benign Prostatic Hyperplasia in Rats.

Authors:  Wenfan Chen; Xiaoqing Huang; Axiang Peng; Tingting Chen; Renzhi Yang; Yuanpeng Huang; Zongbao Yang; Shengyan Xi
Journal:  Evid Based Complement Alternat Med       Date:  2019-05-02       Impact factor: 2.629

6.  Use of Tregs as a cell-based therapy via CD39 for benign prostate hyperplasia with inflammation.

Authors:  Xi Jin; Tianhai Lin; Guang Yang; Huawei Cai; Bo Tang; Xinyang Liao; Huifang Li; Xiaoting Chen; Lina Gong; Hang Xu; Yi Sun; Ping Tan; Jianqiong Yin; Hongwen Ma; Jianzhong Ai; Kunjie Wang; Qiang Wei; Lu Yang; Hong Li
Journal:  J Cell Mol Med       Date:  2020-03-19       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.